department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Trevi Therapeutics, Inc. ($TRVI) · pharmadog

PUBLIC COMPANY

$TRVITrevi Therapeutics, Inc.

New Haven, CT, USupdated 2mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

1

marketed

0

phase 3

1

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Phase 3

nalbuphine hydrochloride ER

Prurigo Nodularis

Opioid receptors; mu/kappa/delta

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Trevi Therapeutics, Inc. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$TRVI

SEC CIK

0001563880

country

US

source

sec_tickers

mentioned in

0news items

entity-linker matched

$TRVI

Insider activity

source: SEC Form 4

routine RSU / option mechanics (5)

Feb 19, 26grantCassella James V · Chief Development Officer215,000 sh
Feb 19, 26grantGalletta Christopher · See Remarks35,000 sh
Feb 19, 26grantSCIASCIA THOMAS · Chief Scientific Officer85,000 sh
Feb 19, 26grantGOOD JENNIFER L · President & CEO675,000 sh
Feb 19, 26grantSimon Farrell · Chief Commercial Officer160,000 sh

Data sources

SEC EDGAR · openFDA

last refreshed 21m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Active trials

phase1NAL ER IPF Respiratory Function and Safety Studyrecruitingn=10
phase2Refractory Chronic Cough Improvement Via NAL ER (RIVER)completedn=66
phase1A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participantsrecruitingn=60
phase1Study of Nalbuphine ER in Participants With Hepatic Impairmentcompletedn=28
phase1A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participantscompletedn=132
phase2Cough Reduction in IPF With Nalbuphine ERcompletedn=165
phase3PRISM Study-Pruritus Relief Through Itch Scratch Modulationcompletedn=353
phase2A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Coughcompletedn=42

more trials →

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?